NASDAQ:HALO Halozyme Therapeutics (HALO) Stock Price, News & Analysis $121.84 0.00 (0.00%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$121.05 -0.79 (-0.65%) As of 09:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Halozyme Therapeutics Stock (NASDAQ:HALO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Halozyme Therapeutics alerts:Sign Up Key Stats Today's Range$120.19▼$122.4550-Day Range$98.66▼$121.8452-Week Range$61.22▼$122.45Volume2.08 million shsAverage Volume2.52 million shsMarket Capitalization$13.83 billionP/E Ratio36.37Dividend YieldN/APrice Target$99.55Consensus RatingModerate Buy Company Overview Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion. Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products. ENHANZE-enabled medicines include subcutaneous formulations such as DARZALEX FASPRO for multiple myeloma, PHESGO for certain forms of breast cancer, and VYVGART HYTRULO for generalized myasthenia gravis. The company also develops and commercializes drug-delivery products and injection technologies through its proprietary business. Founded in 1998 and headquartered in San Diego, California, Halozyme serves international markets primarily through collaborations with global pharmaceutical companies. Its partners are responsible for developing, obtaining regulatory approval for, and commercializing many products that incorporate Halozyme’s technologies, allowing the company’s drug-delivery platforms to support treatments across multiple therapeutic areas and geographies.AI Generated. May Contain Errors. Read More Halozyme Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreHALO MarketRank™: 3.913216560505 of 5 starsHalozyme Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 128th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingHalozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 1 strong buy rating, 9 buy ratings, 2 hold ratings, and 1 sell rating.Downside RiskHalozyme Therapeutics has a consensus price target of $99.55, representing about 18.3% downside from its current price of $121.84.Amount of Analyst CoverageHalozyme Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Halozyme Therapeutics' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth17.81% Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 17.81% in the coming year, from $8.31 to $9.79 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is 36.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.72.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is 36.37, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.28.Price to Earnings Growth RatioHalozyme Therapeutics has a PEG Ratio of 0.46. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 290.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Halozyme Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.82% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 4.54.Change versus previous monthShort interest in Halozyme Therapeutics has recently increased by 0.93%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.87 News SentimentHalozyme Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Halozyme Therapeutics this week, compared to 7 articles on an average week.Search Interest19 people have searched for HALO on MarketBeat in the last 30 days. This is an increase of 217% compared to the previous 30 days.MarketBeat Follows6 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,538,046.00 in company stock.Percentage Held by Insiders2.50% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Halozyme Therapeutics' insider trading history. Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HALO Stock News HeadlinesH.C. Wainwright Reaffirms Their Buy Rating on Halozyme (HALO)October 16 at 1:19 PM | theglobeandmail.comIs Expanded Argenx Deal Altering The Investment Case For Halozyme Therapeutics (HALO)?October 16 at 8:18 AM | finance.yahoo.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 19 at 1:00 AM | Altimetry (Ad)Halozyme Therapeutics (NASDAQ:HALO) Stock Jumps 5.9% After Analyst UpgradeOctober 16 at 1:52 AM | americanbankingnews.comInside Edge’s Todd Gordon: Halozyme Therapeutics are beating estimates; raised full-year guidanceOctober 15, 2026 | msn.comTD Cowen Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) StockOctober 15, 2026 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Stock: Insider Helen Torley Sells 20,000 SharesOctober 9, 2026 | insidertrades.comHalozyme Therapeutics (NASDAQ:HALO) Director Sells 5,230 Shares of StockOctober 3, 2026 | insidertrades.comSee More Headlines HALO Stock Analysis - Frequently Asked Questions How have HALO shares performed this year? Halozyme Therapeutics' stock was trading at $67.30 at the beginning of the year. Since then, HALO shares have increased by 81.0% and is now trading at $121.84. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its earnings results on Thursday, August, 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. The firm's revenue for the quarter was up 47.7% compared to the same quarter last year. Read the conference call transcript. Does Halozyme Therapeutics have any subsidiaries? Halozyme Therapeutics subsidiaries include Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH. Who are Halozyme Therapeutics' major shareholders? Top institutional investors of Halozyme Therapeutics include Congress Asset Management Co. (2.01%), Assenagon Asset Management S.A. (0.35%), State of Alaska Department of Revenue (0.12%) and Koa Wealth Management LLC (0.08%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Bernadette Connaughton, Jeffrey William Henderson, Nicole Labrosse, Mahesh Krishnan, Cortney Caudill and Cortney Caudill. View institutional ownership trends. How do I buy shares of Halozyme Therapeutics? Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Gilead Sciences (GILD), Micron Technology (MU), Palantir Technologies (PLTR), Advanced Micro Devices (AMD) and Intel (INTC). Company Calendar Last Earnings8/06/2026Today10/19/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 HALO's financial health is in the Green zone, according to TradeSmith. HALO has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:HALO CIK1159036 Webwww.halozyme.com Phone858-794-8889Fax858-704-8311Employees423Year Founded1998Price Target and Rating Average Price Target for Halozyme Therapeutics$99.55 High Price Target$130.00 Low Price Target$56.00 Potential Upside/Downside-18.3%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$3.35 Trailing P/E Ratio36.37 Forward P/E Ratio14.66 P/E Growth0.46Net Income$316.89 million Net Margins24.86% Pretax Margin35.06% Return on Equity260.98% Return on Assets23.91% Debt Debt-to-Equity Ratio13.50 Current Ratio2.71 Quick Ratio2.31 Sales & Book Value Annual Sales$1.40 billion Price / Sales9.90 Cash Flow$4.77 per share Price / Cash Flow25.54 Book Value$0.42 per share Price / Book290.10Miscellaneous Outstanding Shares113,500,000Free Float110,661,000Market Cap$13.83 billion OptionableOptionable Beta0.88 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:HALO) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
